Skip to main content
Top
Published in: World Journal of Urology 9/2021

01-09-2021 | Nephrectomy | Original Article

Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy

Authors: Teele Kuusk, Tobias Klatte, Patricia Zondervan, Brunolf Lagerveld, Niels Graafland, Kees Hendricksen, Umberto Capitanio, Andrea Minervini, Grant D. Stewart, Borje Ljungberg, Simon Horenblas, Axel Bex

Published in: World Journal of Urology | Issue 9/2021

Login to get access

Abstract

Purpose

There is sparse evidence on outcomes of resected occult LN metastases at the time of nephrectomy (synchronous disease). We sought to analyse a large international cohort of patients and to identify clinico-pathological predictors of long-term survival.

Materials and methods

We collected data of consecutive patients who underwent nephrectomy and LND for Tany cN0-1pN1 and cM0-1 RCC at 7 referral centres between 1988 and 2019. Patients were stratified into four clinico-pathological groups: (1) cN0cM0-pN1, (2) cN1cM0-pN1(limited, 1–3 positive nodes), (3) cN1cM0-pN1(extensive, > 3 positive nodes), and (4) cM1-pN1. Overall survival (OS) was estimated using the Kaplan–Meier method, and associations with all-cause mortality (ACM) were evaluated using Cox models with multiple imputations.

Results

Of the 4370 patients with LND, 292 patients with pN1 disease were analysed. Median follow-up was 62 months, during which 171 patients died. Median OS was 21 months (95% CI 17–30 months) and the 5-year OS rate was 24% (95% CI 18–31%). Patients with cN0cM0-pN1 disease had a median OS of 57 months and a 5-year OS rate of 43%. 5-year OS (median OS) decreased to 29% (33 months) in cN1cM0-pN1(limited) and to 23% (23 months) in cN1cM0-pN1(extensive) patients. Those with cM1-pN1 disease had the worst prognosis, with a 5-year OS rate of 13% (9 months). On multivariable analysis, age (p = 0.034), tumour size (p = 0.02), grade (p = 0.02) and clinico-pathological group (p < 0.05) were significant predictors of ACM.

Conclusion

Depending on clinico-pathological group, grade and tumour size, 5-year survival of patients with LN metastases varies from 13 to 43%. Patients with resected occult lymph node involvement (cN0/pN1 cM0) have the best prognosis with a considerable chance of long-term survival.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chandrasekar T, Klaassen Z, Goldberg H et al (2017) Metastatic renal cell carcinoma: patterns and predictors of metastases-a contemporary population-based series. Urol Oncol 35(11):661.e7-661.e14CrossRef Chandrasekar T, Klaassen Z, Goldberg H et al (2017) Metastatic renal cell carcinoma: patterns and predictors of metastases-a contemporary population-based series. Urol Oncol 35(11):661.e7-661.e14CrossRef
2.
go back to reference Bhindi B, Wallis CJD, Boorjian SA et al (2018) The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int 121(5):684–698CrossRef Bhindi B, Wallis CJD, Boorjian SA et al (2018) The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int 121(5):684–698CrossRef
3.
go back to reference Delacroix SE Jr, Chapin BF, Chen JJ et al (2011) Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol 186:1236–1241CrossRef Delacroix SE Jr, Chapin BF, Chen JJ et al (2011) Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol 186:1236–1241CrossRef
4.
go back to reference Gershman B, Moreira DM, Thompson RH et al (2017) Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol 72:300–306CrossRef Gershman B, Moreira DM, Thompson RH et al (2017) Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol 72:300–306CrossRef
5.
go back to reference Canfield SE, Kamat AM, Sanchez-Ortiz RF et al (2006) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175:864–869CrossRef Canfield SE, Kamat AM, Sanchez-Ortiz RF et al (2006) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175:864–869CrossRef
6.
go back to reference Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780CrossRef Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780CrossRef
7.
go back to reference Rieken M, Boorjian SA, Kluth LA et al (2019) Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World J Urol 37(8):1631–1637CrossRef Rieken M, Boorjian SA, Kluth LA et al (2019) Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World J Urol 37(8):1631–1637CrossRef
8.
go back to reference Leibovich BC, Lohse CM, Cheville JC, Zaid HB, Boorjian SA, Frank I, Thompson RH, Parker WP (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780CrossRef Leibovich BC, Lohse CM, Cheville JC, Zaid HB, Boorjian SA, Frank I, Thompson RH, Parker WP (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780CrossRef
9.
go back to reference Rosiello G, Palumbo C, Knipper S et al (2020) Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urol Oncol 38:537–544CrossRef Rosiello G, Palumbo C, Knipper S et al (2020) Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urol Oncol 38:537–544CrossRef
10.
go back to reference Blom JH, van Poppel H, Marechal JM et al (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55:28–34CrossRef Blom JH, van Poppel H, Marechal JM et al (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55:28–34CrossRef
11.
go back to reference Bacic J, Liu T, Thompson RH et al (2020) Emulating target clinical trials of radical nephrectomy with or without lymph node dissection for renal cell carcinoma. Urology 140:98–106CrossRef Bacic J, Liu T, Thompson RH et al (2020) Emulating target clinical trials of radical nephrectomy with or without lymph node dissection for renal cell carcinoma. Urology 140:98–106CrossRef
12.
go back to reference Ljungberg B, Albiges L, Abu-Ghanem Y et al (2019) European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75(5):799–810CrossRef Ljungberg B, Albiges L, Abu-Ghanem Y et al (2019) European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75(5):799–810CrossRef
13.
go back to reference Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(5):706–720CrossRef Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(5):706–720CrossRef
14.
go back to reference Motzer RJ, Jonasch E, Agarwal N et al (2015) Kidney cancer, version 3.2015. J Natl Compr Canc Netw 13(2):151–159CrossRef Motzer RJ, Jonasch E, Agarwal N et al (2015) Kidney cancer, version 3.2015. J Natl Compr Canc Netw 13(2):151–159CrossRef
15.
go back to reference Campbell S, Uzzo RG, Allaf ME et al (2017) Renal mass and localized renal cancer: AUA guideline. J Urol 198(3):520–529CrossRef Campbell S, Uzzo RG, Allaf ME et al (2017) Renal mass and localized renal cancer: AUA guideline. J Urol 198(3):520–529CrossRef
16.
go back to reference Pantuck AJ, Zisman A, Dorey F et al (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169:2076–2083CrossRef Pantuck AJ, Zisman A, Dorey F et al (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169:2076–2083CrossRef
17.
go back to reference Whitson JM, Harris CR, Reese AC et al (2011) Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 185:1615–1620CrossRef Whitson JM, Harris CR, Reese AC et al (2011) Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 185:1615–1620CrossRef
18.
go back to reference Karakiewicz PI, Trinh QD, Bhojani N et al (2007) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 51:1616–1624CrossRef Karakiewicz PI, Trinh QD, Bhojani N et al (2007) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 51:1616–1624CrossRef
19.
go back to reference Capitanio U, Suardi N, Matloob R et al (2014) Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int 114:210–215CrossRef Capitanio U, Suardi N, Matloob R et al (2014) Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int 114:210–215CrossRef
20.
go back to reference Golijanin B, Pereira J, Mueller-Leonhard C et al (2019) The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urol Oncol 37(12):932–940CrossRef Golijanin B, Pereira J, Mueller-Leonhard C et al (2019) The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urol Oncol 37(12):932–940CrossRef
21.
go back to reference Kuusk T, Zondervan P, Lagerveld B et al (2020) Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. Urol Oncol 38(5):521–525CrossRef Kuusk T, Zondervan P, Lagerveld B et al (2020) Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. Urol Oncol 38(5):521–525CrossRef
22.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours, 7th edn. Wiley-Blackwell, Chichester, pp 255–257 Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours, 7th edn. Wiley-Blackwell, Chichester, pp 255–257
23.
go back to reference White IR, Royston P (2009) Imputing missing covariate values for the Cox model. Stat Med 28:1982–1998CrossRef White IR, Royston P (2009) Imputing missing covariate values for the Cox model. Stat Med 28:1982–1998CrossRef
24.
go back to reference Marshall A, Altman DG, Holder RL et al (2009) Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 9:57CrossRef Marshall A, Altman DG, Holder RL et al (2009) Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 9:57CrossRef
25.
go back to reference Belsante M, Darwish O, Youssef R et al (2014) Lymphovascular invasion in clear cell renal cell carcinoma-association with disease-free and cancer-specific survival. Urol Oncol 32(1):30.e23–8CrossRef Belsante M, Darwish O, Youssef R et al (2014) Lymphovascular invasion in clear cell renal cell carcinoma-association with disease-free and cancer-specific survival. Urol Oncol 32(1):30.e23–8CrossRef
26.
go back to reference Yu KJ, Keskin SK, Meissner MA et al (2018) Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer 124(20):4023–4031CrossRef Yu KJ, Keskin SK, Meissner MA et al (2018) Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer 124(20):4023–4031CrossRef
27.
go back to reference Zareba P, Russo P (2019) The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. Urol Oncol 37(5):302.e1-302.e6CrossRef Zareba P, Russo P (2019) The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. Urol Oncol 37(5):302.e1-302.e6CrossRef
28.
go back to reference Terrone C, Cracco C, Porpiglia F et al (2006) Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49(2):324–331CrossRef Terrone C, Cracco C, Porpiglia F et al (2006) Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49(2):324–331CrossRef
29.
go back to reference Trinh QD, Schmitges J, Bianchi M et al (2012) Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. BJU Int 110:E21–E27CrossRef Trinh QD, Schmitges J, Bianchi M et al (2012) Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. BJU Int 110:E21–E27CrossRef
30.
go back to reference Bex A, Vermeeren L, de Windt G et al (2010) Feasibility of sentinel node detection in renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging 37(6):1117–1123CrossRef Bex A, Vermeeren L, de Windt G et al (2010) Feasibility of sentinel node detection in renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging 37(6):1117–1123CrossRef
31.
go back to reference Kuusk T, De Bruijn R, Brouwer OR et al (2018) Lymphatic drainage from renal tumors in vivo: a prospective sentinel node study using SPECT/CT imaging. J Urol 199(6):1426–1432CrossRef Kuusk T, De Bruijn R, Brouwer OR et al (2018) Lymphatic drainage from renal tumors in vivo: a prospective sentinel node study using SPECT/CT imaging. J Urol 199(6):1426–1432CrossRef
32.
go back to reference Verhoeff SR, van Es SC, Boon E et al (2019) Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 46(9):1931–1939CrossRef Verhoeff SR, van Es SC, Boon E et al (2019) Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 46(9):1931–1939CrossRef
Metadata
Title
Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy
Authors
Teele Kuusk
Tobias Klatte
Patricia Zondervan
Brunolf Lagerveld
Niels Graafland
Kees Hendricksen
Umberto Capitanio
Andrea Minervini
Grant D. Stewart
Borje Ljungberg
Simon Horenblas
Axel Bex
Publication date
01-09-2021
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 9/2021
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-021-03633-5

Other articles of this Issue 9/2021

World Journal of Urology 9/2021 Go to the issue